Researchers report encouraging tumor response and survival data for sacituzumab govitecan in recurrent uterine cancer, offering potential new hope for patients whose disease progressed after chemotherapy and immunotherapy. The post Antibody-Drug Conjugate Shows Activity in Hard-to-Treat Uterine Cancer appeared first on Inside Precision Medicine .